

Neil H Shear

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1988774/publications.pdf>

Version: 2024-02-01

171
papers

5,399
citations

87723

38
h-index

98622

67
g-index

196
all docs

196
docs citations

196
times ranked

4824
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. <i>British Journal of Dermatology</i> , 2007, 157, 934-940.	1.4	290
2	Antifungal agents: An overview. Part II. <i>Journal of the American Academy of Dermatology</i> , 1994, 30, 911-933.	0.6	252
3	Recommendations for <scp>HLA</scp>â€B*15:02 and <scp>HLA</scp>â€A*31:01 genetic testing to reduce the risk of carbamazepineâ€induced hypersensitivity reactions. <i>Epilepsia</i> , 2014, 55, 496-506.	2.6	173
4	Onychomycosis in the 21st Century: An Update on Diagnosis, Epidemiology, and Treatment. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 525-539.	0.6	168
5	Gender Differences in Adverse Drug Reactions. <i>Journal of Clinical Pharmacology</i> , 1998, 38, 1003-1009.	1.0	167
6	A validation study of The Geriatric Depression Scale short form. <i>International Journal of Geriatric Psychiatry</i> , 1996, 11, 457-460.	1.3	157
7	Stevensâ€Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. <i>American Journal of Clinical Dermatology</i> , 2015, 16, 475-493.	3.3	151
8	Onychomycosis: a review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1972-1990.	1.3	148
9	Controversies in drug allergy: Testing for delayed reactions. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 66-73.	1.5	144
10	Antiepileptic Drug Hypersensitivity Syndrome. <i>Epilepsia</i> , 1998, 39, S3-S7.	2.6	143
11	Recurrence and Outcomes of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children. <i>Pediatrics</i> , 2011, 128, 723-728.	1.0	139
12	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 38-69.	2.0	134
13	Azathioprine hypersensitivity-like reactions-a case report and a review of the literature. <i>Clinical and Experimental Dermatology</i> , 1995, 20, 353-356.	0.6	131
14	An Overview of Topical Antifungal Therapy in Dermatomycoses. <i>Drugs</i> , 1998, 55, 645-674.	4.9	117
15	HLA-A*31:01 and HLA-B*15:02 as Genetic Markers for Carbamazepine Hypersensitivity in Children. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 142-149.	2.3	110
16	Terbinafine: An update. <i>Journal of the American Academy of Dermatology</i> , 1997, 37, 979-988.	0.6	104
17	Phenotype Standardization for Immune-Mediated Drug-Induced Skin Injury. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 896-901.	2.3	99
18	Tinea capitis in children: a systematic review of management. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2264-2274.	1.3	85

#	ARTICLE	IF	CITATIONS
19	Advances in the Diagnosis of Adverse Drug Reactions. <i>Journal of Clinical Pharmacology</i> , 1992, 32, 897-904.	1.0	83
20	Lamotrigine-Induced Severe Cutaneous Adverse Reactions. <i>Epilepsia</i> , 1998, 39, S22-S26.	2.6	81
21	Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. <i>British Journal of Dermatology</i> , 2014, 170, 1341-1349.	1.4	81
22	A Risk-Benefit Assessment of the Newer Oral Antifungal Agents Used to Treat Onychomycosis. <i>Drug Safety</i> , 2000, 22, 33-52.	1.4	76
23	Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2112-2125.	1.3	68
24	Management of acne: Canadian clinical practice guideline. <i>Cmaj</i> , 2016, 188, 118-126.	0.9	67
25	Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>British Journal of Dermatology</i> , 2016, 175, 422-424.	1.4	64
26	Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 313-316.	0.6	54
27	Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1028-1036.	2.3	52
28	The health status of obese individuals in Canada. <i>International Journal of Obesity</i> , 2001, 25, 662-668.	1.6	51
29	Sulfonamide Hypersensitivity: Fact and Fiction. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2116-2123.	2.0	50
30	The Growing Problem of Antifungal Resistance in Onychomycosis and Other Superficial Mycoses. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 149-157.	3.3	49
31	What Will Be the Role of Pharmacogenetics in Evaluating Drug Safety and Minimising Adverse Effects?. <i>Drug Safety</i> , 2001, 24, 75-85.	1.4	48
32	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): How Far Have We Come?. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 217-236.	3.3	48
33	The new oral antifungal agents for onychomycosis of the toenails. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1999, 13, 1-13.	1.3	47
34	Drug-Induced Pyoderma Gangrenosum: A Review. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 67-77.	3.3	47
35	A review of drug patch testing and implications for HIV clinicians. <i>Aids</i> , 2008, 22, 999-1007.	1.0	45
36	Epidemiology of severe drug hypersensitivity. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, 2-9.	1.6	45

#	ARTICLE	IF	CITATIONS
37	Lymphomatoid papulosis: an update and review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 59-73.	1.3	42
38	Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. <i>British Journal of Dermatology</i> , 1994, 130, 32-34.	1.4	41
39	SJS/TEN 2019: From science to translation. <i>Journal of Dermatological Science</i> , 2020, 98, 2-12.	1.0	41
40	The Efficacy of Platelet-Rich Plasma in the Field of Hair Restoration and Facial Aestheticsâ€”A Systematic Review and Meta-analysis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 185-203.	0.6	40
41	Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004, 8, 321-337.	0.6	39
42	Global perspectives for the management of onychomycosis. <i>International Journal of Dermatology</i> , 2019, 58, 1118-1129.	0.5	39
43	Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 572-581.	0.6	36
44	Severe Physical Complications among Survivors of Stevensâ€™Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Drug Safety</i> , 2018, 41, 277-284.	1.4	34
45	Pemphigus herpetiformis: a case series and review of the literature. <i>International Journal of Dermatology</i> , 2015, 54, 1014-1022.	0.5	32
46	Confirmatory Testing Prior to Initiating Onychomycosis Therapy Is Cost-Effective. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 129-141.	0.6	32
47	Mechanisms of Alcoholic Liver Disease: Cytokines. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 251S-253S.	1.4	31
48	2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 375-431.	0.6	28
49	Onychomycosis in children: Safety and efficacy of antifungal agents. <i>Pediatric Dermatology</i> , 2018, 35, 552-559.	0.5	28
50	Comparison of Management Guidelines for Moderate-to-Severe Plaque Psoriasis: A Review of Phototherapy, Systemic Therapies, and Biologic Agents. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 204-221.	0.6	28
51	Monotherapy for toenail onychomycosis: a systematic review and network meta-analysis. <i>British Journal of Dermatology</i> , 2020, 182, 287-299.	1.4	28
52	Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 801-803.	0.6	27
53	A Practical Guide to Curing Onychomycosis: How to Maximize Cure at the Patient, Organism, Treatment, and Environmental Level. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 123-133.	3.3	27
54	Beta-lactam-induced immediate hypersensitivity reactions: A genome-wide association study of a deeply phenotyped cohort. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1830-1837.e15.	1.5	26

#	ARTICLE	IF	CITATIONS
55	Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome. <i>World Journal of Clinical Cases</i> , 2019, 7, 705-716.	0.3	26
56	Impact of Cosmetic Camouflage on the Quality of Life of Children With Skin Disease and Their Families. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 211-215.	0.6	25
57	A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 623-626.	0.6	25
58	Cost and Resource Use of Pemphigus and Pemphigoid Disorders Pre- and Post-Rituximab. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 274-282.	0.6	24
59	Scientific evidence for the use of current traditional systemic therapies in patients with hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, S42-S46.	0.6	24
60	Enhanced differential diagnosis of anticonvulsant hypersensitivity reactions by an integrated Bayesian and biochemical approach. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 564-575.	2.3	23
61	Supportive care in the acute phase of Stevensâ€Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphiâ€based consensus. <i>British Journal of Dermatology</i> , 2021, 185, 616-626.	1.4	22
62	ANAPHYLAXIS FROM BACITRACIN AND POLYMYXIN B (POLYSPORIN) OINTMENT. <i>International Journal of Dermatology</i> , 1995, 34, 572-573.	0.5	21
63	Clinical and Economic Factors in the Treatment of Onychomycosis. <i>Pharmacoeconomics</i> , 1996, 9, 307-320.	1.7	21
64	Common drug-drug interactions in antifungal treatments for superficial fungal infections. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 387-398.	1.5	21
65	Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 290-296.	0.6	21
66	Antibiofilm Treatment for Onychomycosis and Chronic Fungal Infections. <i>Skin Appendage Disorders</i> , 2018, 4, 136-140.	0.5	21
67	Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>JAMA Dermatology</i> , 2021, 157, 301.	2.0	21
68	Neuroblastoma after prenatal exposure to phenytoin: Cause and effect?. <i>Teratology</i> , 1989, 40, 157-162.	1.8	20
69	Improving the Diagnosis of Hypersensitivity Reactions Associated with Sulfonamides. <i>Journal of Clinical Pharmacology</i> , 1994, 34, 1228-1233.	1.0	20
70	Quantifying the Costs of Serious Adverse Drug Reactions to Antiepileptic Drugs. <i>Epilepsia</i> , 1998, 39, S27-S32.	2.6	20
71	Granulomatous Drug Eruptions. <i>Dermatologic Clinics</i> , 2015, 33, 525-539.	1.0	20
72	Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matchingâ€adjusted indirect comparison. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1107-1115.	1.3	20

#	ARTICLE	IF	CITATIONS
73	Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double-blind placebo-controlled study. <i>Journal of Dermatological Treatment</i> , 2000, 11, 33-37.	1.1	19
74	Acitretin. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 48-53.	0.6	19
75	A Paradigm Shift in the Treatment and Management of Onychomycosis. <i>Skin Appendage Disorders</i> , 2021, 7, 351-358.	0.5	18
76	BETAMETHASONE DIPROPIONATE POLYACRYLIC FILM-FORMING LOTION IN THE TREATMENT OF HAND DERMATITIS. <i>International Journal of Dermatology</i> , 1993, 32, 828-829.	0.5	16
77	Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study. <i>Clinical Therapeutics</i> , 2018, 40, 415-429.e6.	1.1	16
78	Granulomatous Cutaneous Drug Eruptions: A Systematic Review. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 39-53.	3.3	16
79	The increasing problem of treatment-resistant fungal infections: a call for antifungal stewardship programs. <i>International Journal of Dermatology</i> , 2021, 60, e474-e479.	0.5	16
80	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Drug-Induced Hypersensitivity Syndrome (DiHS) – Readdressing the DRESS. <i>Biomedicines</i> , 2022, 10, 999.	1.4	16
81	Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 390-394.	2.3	15
82	Methotrexate in the Treatment of Moderate to Severe Atopic Dermatitis: A Retrospective Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 484-487.	0.6	15
83	The Direct Medical Costs Associated with Suspected and Confirmed Cases of Heparin-Induced Thrombocytopenia. <i>Blood</i> , 2007, 110, 972-972.	0.6	15
84	Treatment of toxic epidermal necrolysis in North America. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 876-877.e2.	0.6	14
85	Ultrasound and Infrared-Based Imaging Modalities for Diagnosis and Management of Cutaneous Diseases. <i>Frontiers in Medicine</i> , 2018, 5, 115.	1.2	14
86	Long-term dupilumab treatment for chronic refractory generalized prurigo nodularis: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1049-1051.	0.6	14
87	Oral lichen planus: a novel staging and algorithmic approach and all that is essential to know. <i>F1000Research</i> , 2020, 9, 206.	0.8	14
88	The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 580-588.	1.3	13
89	Onychomycosis in children – review on treatment and management strategies. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1213-1224.	1.1	13
90	Management of Drug-Induced Toxic Epidermal Necrolysis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2000, 4, 96-102.	0.6	12

#	ARTICLE	IF	CITATIONS
91	Cutaneous Drug Reactions in the Elderly. <i>Drugs and Aging</i> , 2017, 34, 655-672.	1.3	12
92	What are some of the lessons learnt from in vitro studies of severe unpredictable drug reactions?. <i>British Journal of Dermatology</i> , 2000, 142, 206-207.	1.4	11
93	Loss of Work Productivity and Quality of Life in Patients With Autoimmune Bullous Dermatoses. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 546-554.	0.6	11
94	Associated Hematolymphoid Malignancies in Patients With Lymphomatoid Papulosis: A Canadian Retrospective Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 507-512.	0.6	11
95	Calcipotriol in the Treatment of Psoriasis of Limited Severity: Pharmacoeconomic Evaluation. <i>Journal of Cutaneous Medicine and Surgery</i> , 1997, 2, 7-15.	0.6	10
96	Drug-Related Mortality in Canada (1984-1994)., 1997, 6, 157-168.		10
97	A questionnaire study on the management of onychomycosis: a Canadian perspective. <i>International Journal of Dermatology</i> , 1998, 37, 457-460.	0.5	10
98	Maintenance of therapeutic response after 1Âyear of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 953-956.	0.6	10
99	Radiation dermatitis assessment tools used in breast cancer: A systematic review of measurement properties. <i>Supportive Care in Cancer</i> , 2021, 29, 2265-2278.	1.0	10
100	Blistering severe cutaneous adverse reactions in children: proposal for paediatricâ€focused clinical criteria. <i>British Journal of Dermatology</i> , 2021, 185, 447-449.	1.4	10
101	Lithium augmentation in geriatric depressed outpatients: A clinical report. <i>International Journal of Geriatric Psychiatry</i> , 1994, 9, 995-1002.	1.3	9
102	Multinational pharmacoeconomic analysis of topical and oral therapies for onychomycosis. <i>Journal of Dermatological Treatment</i> , 1997, 8, 229-235.	1.1	9
103	Pharmacoeconomic analysis of topical treatments for tinea infections. <i>International Journal of Dermatology</i> , 1998, 37, 64-71.	0.5	9
104	Needs Survey of Canadian Rosacea Patients. <i>Journal of Cutaneous Medicine and Surgery</i> , 1999, 3, 178-181.	0.6	9
105	Clinical and Economic Implications of Non-Adherence to HAART in HIV Infection. <i>Disease Management and Health Outcomes</i> , 2002, 10, 85-91.	0.3	9
106	Managing skin toxicities related to panitumumab. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 754-759.	0.6	9
107	Bath Psoralen-ultraviolet A and Narrowband Ultraviolet B Phototherapy as Initial Therapy for Early-stage Mycosis Fungoides: A Retrospective Cohort of 267 Cases at the University of Toronto. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 604-612.	0.2	9
108	Organization and Functioning of an Adverse Drug Reaction Clinic. <i>Journal of Clinical Pharmacology</i> , 1994, 34, 68-79.	1.0	8

#	ARTICLE	IF	CITATIONS
109	What Is the Risk of Harm Associated With Topical Calcineurin Inhibitors?. Journal of Cutaneous Medicine and Surgery, 2019, 23, 19S-26S.	0.6	8
110	Diagnostic and therapeutic approach to scalp dysesthesia: A case series and published work review. Journal of Dermatology, 2019, 46, 526-530.	0.6	8
111	Serious adverse reactions induced by minocycline.. Clinical Pharmacology and Therapeutics, 1996, 59, 159-159.	2.3	7
112	Onychomycosis and Chronic Fungal Disease: Exploiting a Commensal Disguise to Stage a Covert Invasion. Journal of Cutaneous Medicine and Surgery, 2018, 22, 318-322.	0.6	7
113	Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1373-1376.	1.3	7
114	A practical application of onychomycosis cure – combining patient, physician and regulatory body perspectives. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 281-287.	1.3	7
115	Retrospective Study of Patients With SJS/TEN Treated at a Tertiary Burn Unit in Canada: Overview of 17 Years of Treatment. Journal of Cutaneous Medicine and Surgery, 2021, 25, 271-280.	0.6	7
116	Ultra high-frequency ultrasound with seventy-MHz transducer in hair disorders: Development of a novel noninvasive diagnostic methodology. Journal of Dermatological Science, 2021, 102, 167-176.	1.0	7
117	The new oral antifungal agents for onychomycosis of the toenails. , 1999, 13, 1.		7
118	Terbinafine for the treatment of pedal onychomycosis. A foot closer to the promised land of cured nails?. Archives of Dermatology, 1995, 131, 937-42.	1.7	7
119	The Evolution of Topical Formulations in Psoriasis. Skin Therapy Letter, 2018, 23, 5-9.	0.3	7
120	A Double-Blind, Randomized, Placebo-Controlled Trial of Eutectic Lidocaine/Prilocaine Cream 5% (EMLA)® for Analgesia Prior to Cryotherapy of Warts in Children and Adults. Pediatric Dermatology, 2009, 15, 129-133.	0.5	6
121	Influence of the phenotype on mycosis fungoides prognosis, a retrospective cohort study of 160 patients. International Journal of Dermatology, 2019, 58, 933-939.	0.5	6
122	Toxic Epidermal Necrolysis Spectrum Management at Sunnybrook Health Sciences Centre: Our Multidisciplinary Approach After Review of the Current Evidence. Journal of Cutaneous Medicine and Surgery, 2018, 22, 213-219.	0.6	6
123	Azathioprine hypersensitivity reactions: Caution upon rechallenge. , 1997, 20, 1467-1467.		5
124	Quantification of randomness (Entropy) as a clinical tool to assess the severity of skin disease. Medical Hypotheses, 2019, 132, 109311.	0.8	5
125	Immune checkpoint inhibitor-related alopecia: Insight into the pathophysiology utilizing non-invasive diagnostic techniques. Journal of Dermatology, 2019, 46, e152-e153.	0.6	5
126	Labeled use of efinaconazole topical solution 10% in treating onychomycosis in children and a review of the management of pediatric onychomycosis. Dermatologic Therapy, 2020, 33, e13613.	0.8	5

#	ARTICLE	IF	CITATIONS
127	Systemic glucocorticoids: important issues and practical guidelines for the dermatologist. <i>International Journal of Dermatology</i> , 2015, 54, 723-729.	0.5	4
128	An update on the safety of apremilast for the treatment of plaque psoriasis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 403-408.	1.0	4
129	Vemurafenib-induced DRESS/DIHS resulting in spontaneous melanoma regression: an immunological reaction shedding new light on melanoma treatment?. <i>International Journal of Dermatology</i> , 2020, 59, e139-e141.	0.5	4
130	Management of Pain Associated with Selected Conditions in Dermatology. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 463-474.	3.3	3
131	The 9th International Congress on Cutaneous Adverse Drug Reactions at the 23rd World Congress of Dermatology in Vancouver, 2015. <i>Drug Safety</i> , 2016, 39, 271-276.	1.4	3
132	Canada's Study of Adherence Outcomes in Patients Receiving Adalimumab: 3-year Results From the COMPANION Study. <i>Clinical Therapeutics</i> , 2018, 40, 1024-1032.	1.1	3
133	Long-term 52-week trends in apremilast safety outcomes for treatment of psoriasis in clinical practice: a multicentre, retrospective case series. <i>British Journal of Dermatology</i> , 2019, 180, 211-212.	1.4	3
134	Knowledge and opinions among Canadian academic physicians regarding genetic screening to prevent severe cutaneous adverse drug reactions. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1401-1405.	0.6	3
135	Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 282-288.	0.6	3
136	Validation of artificial intelligence application in clinical dermatology. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 201-203.	0.6	3
137	Practical Management of Patients with Atopic Dermatitis on Dupilumab. <i>Dermatology and Therapy</i> , 2021, 11, 1805-1828.	1.4	3
138	Perception and Experience of Biologic Therapy in Atopic Dermatitis: A Qualitative Focus Group Study of Physicians and Patients in Europe and Canada. <i>Dermatology and Therapy</i> , 2021, 11, 2159-2177.	1.4	3
139	Pharmacogenetics and cutaneous drug reactions. <i>Seminars in Dermatology</i> , 1989, 8, 219-26.	0.6	3
140	Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e544-e547.	1.3	2
141	Sunnybrook Protocol for Treatment of Toxic Epidermal Necrolysis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 535-535.	0.6	2
142	The 10th International Congress on Cutaneous Adverse Drug Reactions, Shimane, Japan, 2018: Focus on New Discoveries. <i>Drug Safety</i> , 2019, 42, 797-801.	1.4	2
143	Pseudotrichoscopic findings from colour product use: a retrospective analysis and a test to reproduce findings. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 360-362.	0.6	2
144	Oral Methotrexate Monotherapy for Severe Alopecia Areata: A Single Center Retrospective Case Series. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 490-497.	0.6	2

#	ARTICLE	IF	CITATIONS
145	A validation study of The Geriatric Depression Scale short form. , 1996, 11, 457.		2
146	An Atypical Case of Mucocutaneous Blastomycosis in the Greater Toronto Area. Journal of Cutaneous Medicine and Surgery, 2017, 21, 263-266.	0.6	1
147	Oral isotretinoin: ensuring safe use while not limiting access to those who need it. Cmaj, 2017, 189, E510-E510.	0.9	1
148	Early-stage mycosis fungoides screening investigations: a retrospective analysis of 440 cases. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e217-e218.	1.3	1
149	The Need to Evaluate Risks and Benefits of Pharmacists Independently Diagnosing and Treating Dermatologic Conditions in Canada. Journal of Cutaneous Medicine and Surgery, 2019, 23, 556-557.	0.6	1
150	The Need to Evaluate Risks and Benefits of Ontario Nurse Practitioners Performing Cosmetic Procedures Following Amendments to the Ontario Nursing Act 1991. Journal of Cutaneous Medicine and Surgery, 2020, 24, 101-103.	0.6	1
151	Biosimilars: Promises Made. Promises Kept?. Journal of Cutaneous Medicine and Surgery, 2021, 25, 241-242.	0.6	1
152	Bruton tyrosine kinase inhibition warrants further study for pemphigus. British Journal of Dermatology, 2021, 185, 691-692.	1.4	1
153	A validation study of The Geriatric Depression Scale short form. , 1996, 11, 457.		1
154	Sezary Syndrome and Combination Immunomodulatory Therapy: Improving Clinical Outcomes. Blood, 2008, 112, 4957-4957.	0.6	1
155	Comprehensiveness of Quality of Life Instruments in Capturing Concerns Related to Chemotherapy-Induced Neutropenia. Blood, 2008, 112, 1311-1311.	0.6	1
156	Management of Drug-Induced Epidermal Necrolysis (DEN) in Pediatric Patients: Moving from Drug-Induced Stevens-Johnson Syndrome, Overlap and Toxic Epidermal Necrolysis to a Single Unifying Diagnosis of DEN. Paediatric Drugs, 2022, 24, 307-319.	1.3	1
157	Morphine in kidney failure. Clinical Pharmacology and Therapeutics, 1994, 56, 114-114.	2.3	0
158	Pharmacoeconomics for Dermatologists: An Introduction. Journal of Cutaneous Medicine and Surgery, 1997, 1, 185-189.	0.6	0
159	The Risks of Systemic Corticosteroid Use. Journal of Urology, 1999, 161, 2026-2026.	0.2	0
160	Effect of concomitant statin use on rituximab treatment for pemphigus and pemphigoid disorders: a case-based review. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 520-522.	1.3	0
161	Eosinophils in the skin—a red herring masking lymphoma: a case series. SAGE Open Medical Case Reports, 2018, 6, 2050313X1877312.	0.2	0
162	New Perspectives on Topical Calcineurin Inhibitors: Role in Dermatology Today and Into the Future. Journal of Cutaneous Medicine and Surgery, 2019, 23, 3S-4S.	0.6	0

#	ARTICLE	IF	CITATIONS
163	A progressive breast skin detachment in a breast cancer survivor. Breast Journal, 2020, 26, 1041-1042.	0.4	0
164	Refractory vitiligo improving with eculizumab. Dermatologic Therapy, 2020, 33, e13233.	0.8	0
165	The Need to Evaluate the Risks and Benefits Posed by Quebec Bill 43 Expanding Nurse Practitionersâ€™™ Scope of Practice. Journal of Cutaneous Medicine and Surgery, 2020, 24, 426-427.	0.6	0
166	Cutaneous Drug Reactions With Systemic Features. , 2021, , 743-752.e4.		0
167	The Cost of HIT-Safe Anticoagulant Use at a Tertiary Care, Adult, Academic Hospital.. Blood, 2008, 112, 1293-1293.	0.6	0
168	Early intervention of skin toxicities by panitumumab and clinical outcomes in the clinical setting.. Journal of Clinical Oncology, 2014, 32, e20673-e20673.	0.8	0
169	Epidermal Necrolysis Spectrum from Basic Theory to Practice Essentials. , 2020, , 549-557.		0
170	Time to codify a challenge in communication. Journal of Dermatological Treatment, 2022, , 1-2.	1.1	0
171	Some symptoms of the eosinophilia-myalgia syndrome were unresolved at 1 year. ACP Journal Club, 1992, 116, 25.	0.1	0